Targeting a specific enzyme to develop new treatments for chronic pain
Pharmacological validation of adenylyl cyclase 1 as a drug target for chronic pain
This study is looking at a new way to help people with chronic pain by testing a special target in the body that could lead to safer pain relief options without the risk of addiction.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Purdue University NIH-funded |
| Lab location | 1 site (West Lafayette, United States) |
| Project ID | NIH-11054726 on NIH RePORTER |
What this research studies
This research investigates the potential of adenylyl cyclase type 1 (AC1) as a new target for treating chronic pain, which affects millions of people and often leads to drug dependency. By using animal models, the researchers are exploring how inhibiting AC1 can reduce inflammatory and neuropathic pain. They have identified promising chemical compounds that may serve as effective AC1 inhibitors and are working on optimizing these compounds for better efficacy and safety. The goal is to develop new medications that provide pain relief without the risk of addiction.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals experiencing chronic pain conditions, particularly those who have not found relief from existing treatments.
Not a fit: Patients with acute pain or those who do not have chronic pain conditions may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to the development of safer and more effective pain relief medications for patients suffering from chronic pain.
How similar studies have performed: Previous research has shown promise in targeting AC1 for pain relief, indicating that this approach could lead to significant advancements in chronic pain treatment.
Where this research is happening
West Lafayette, United States
- Purdue University — West Lafayette, United States (Active)
Researchers
- Principal investigator: Flaherty, Daniel Patrick — Purdue University
- Study coordinator: Flaherty, Daniel Patrick
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.